Principal Financial Group Inc. Increases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Principal Financial Group Inc. raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 285,411 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,566 shares during the period. Principal Financial Group Inc. owned 0.52% of Supernus Pharmaceuticals worth $8,899,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of SUPN. GAMMA Investing LLC increased its stake in shares of Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 398 shares during the period. EntryPoint Capital LLC purchased a new position in Supernus Pharmaceuticals during the 1st quarter valued at $43,000. Meeder Asset Management Inc. bought a new position in Supernus Pharmaceuticals in the 2nd quarter worth $47,000. Innealta Capital LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth about $51,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 352 shares during the period.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $35.25 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $39.37. The firm has a 50-day moving average of $33.38 and a 200 day moving average of $30.96. The stock has a market cap of $1.95 billion, a P/E ratio of 32.94 and a beta of 0.86.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same quarter last year, the firm earned ($0.29) earnings per share. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. Research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Frank Mottola sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the transaction, the senior vice president now directly owns 8,200 shares of the company’s stock, valued at approximately $303,236. This represents a 64.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the sale, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. This represents a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock worth $5,660,180 over the last three months. 9.30% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.